# Corlieve Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corlieve-therapeutics

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.corlieve.com
- Total disclosed funding: $6.7M
- Latest round: Series A (Oct 16, 2020)
- Investors on record: 5

## About

Corlieve Therapeutics SAS is a biotechnology company focusing on innovative gene therapies aimed at treating neurological disorders, leveraging advanced miRNA silencing technology to develop its therapeutic pipeline.Founded in 2019 and headquartered in Paris, France, Corlieve Therapeutics SAS specializes in gene therapies for neurological disorders. In June 2021, the company was acquired by UniQure N.V. for EUR 46.3 million from BB Pureos Bioventures and others, marking a strategic pivot in its business operations. The acquisition positions Corlieve within a robust portfolio aimed at expanding innovative treatment options. The company's focus on miRNA silencing technology is expected to enhance its contributions to gene therapy development in the sector.Corlieve Therapeutics SAS develops a range of gene therapies specifically designed to target neurological disorders. Their innovative approach utilizes miRNA silencing technology to create effective treatments. The focus is primarily on advancing the therapeutic pipeline aimed at addressing significant unmet medical needs in neurology, enhancing patient outcomes through targeted interventions.As of 2023, Corlieve Therapeutics SAS reported an EBITDA of EUR -13,676,160.60, reflecting the early stage of its business model as it continues to invest heavily in research and development to bring its therapies to market.Following the acquisition by UniQure N.V. in June 2021, Corlieve Therapeutics SAS plans to leverage the funding to accelerate the development of its pipeline focused on innovative gene therapies for neurological disorders. The acquisition will also support its expansion into new markets, including North America and Asia, by enhancing its global leadership in gene therapy. The company aims to introduce new therapeutic products targeting various neurological conditions by 2025, aiming for substantial advancements in treatment options available to patients.

## Funding rounds

- Series A, Oct 16, 2020, $1.8M — Pureos Bioventures
- Series A, Feb 5, 2020, $5M — Eurazeo, Kurma Partners, REGENXBIO Inc., Aquitaine Science Transfert

## Investors

- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- REGENXBIO Inc. — Series A
- Aquitaine Science Transfert (https://capitalatlas.ai/funds/aquitaine-science-transfert) — Series A
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series A